Centessa Pharmaceuticals plc
CNTA$3.67B
Mid CapNASDAQBiotechnology🇺🇸North America114 employees
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Apr 30, 2026
11wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
2 upcoming, 0 past
Phase 2Next
ORX750 Phase 2 Results Expected
Apr 30, 2026ORX75090
Primary completion for ORX750 trial (NCT07096674) in Narcolepsy Type 1
Source🎯PDUFA
FDA PDUFA Date epilepsy drug
December 2026~
For epilepsy. NDA submitted. AI-extracted from: Praxis tees up another approval filing; Geron turns to layoffs
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
ORX750 | Phase 2 | Narcolepsy Type 1 | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
CNTA News